Clinical Trial Results

Viewing Page 1 of 1 | Showing Results 1 - 4 of 4

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (COSMIC-021)

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib...

Matthew Taylor, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

RWF: A Phase I Study of GNX102 in patients with Advanced Solid Tumors

GNX-001 is an open-label, phase 1, multicenter, dose-escalation and expansion study of GNX102 infused every 21 days. Approximately 30 patients may...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability,...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

RWF: Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

The primary objectives of this study are : to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
Viewing Page 1 of 1 | Showing Results 1 - 4 of 4